| Today’s Big NewsFeb 20, 2024 |
| By Fraiser Kansteiner Robert Michael, AbbVie’s current president and chief operating officer, has been tapped by the company’s board of directors to take over Richard Gonzalez’s CEO post on July 1. Gonzalez, for his part, is retiring from his role as chief executive after 11 years to become executive chairman of AbbVie’s board. |
|
|
|
By Nick Paul Taylor Sanofi’s HIMALAYA adventure has ended in failure, dealing another blow to its RIPK1 collaboration with Denali Therapeutics. |
By Andrea Park More than a year after laying out a plan to divest its patient monitoring and respiratory interventions businesses—sparking months of speculation over potential buyers—Medtronic is reworking the reorganization. |
By Angus Liu AstraZeneca is celebrating a trio of advancements for its portfolio in non-small cell lung cancer, including an “overwhelming efficacy benefit” for Tagrisso in early-stage disease. Besides the trial result, AZ touted an FDA approval for Tagrisso's chemo combo in metastatic tumors, plus an application acceptance for a Daiichi Sankyo-partnered TROP2 antibody-drug conjugate in a patient subgroup. |
|
Thursday, March 7, 2024 | 2pm ET / 11am PT Join us for this discussion on the future of cloud computing in healthcare. Learn key insights on the investments being made to advance research and commercial efforts. We will explore topics such as data sharing without data movement, the future of analytics and privacy, the use of ML models for lookalike audiences supported by cloud computing, and more. Register now. 
|
|
By Max Bayer Rapt Therapeutics is reeling from an “unfortunate and unexpected” clinical hold after a patient in a phase 2 immunology trial experienced liver failure that may be related to the study drug. |
By Angus Liu The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind immunotherapy developed by Iovance Biotherapeutics. |
By Andrea Park “Progress is good, and the patient seems to have made a full recovery, with no ill effects that we are aware of,” the Neuralink founder said Monday. |
By James Waldron The collaboration between Everest Medicines and Providence Therapeutics back in 2021 marked a significant step up for the Chinese mRNA sector. Now, Everest will continue the ascent alone. |
By Fraiser Kansteiner Aiming to beef up development and manufacturing of antibody-drug conjugates, Daiichi Sankyo is plugging roughly €1 billion ($1.08 billion) into an expansion of its production facility in Pfaffenhofen an der Ilm, Germany. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Max Bayer from Fierce Biotech explores the future of gene editing in an interview with the CEO of Verve Therapeutics. |
|
|---|
|
|
|
Wednesday, March 13, 2024 | 11:00am ET/ 8:00am PT Extractables and leachables are a hot topic in the pharmaceutical industry today. As single-use systems, devices, and routes of administration evolve, it is important to have a strategy that helps ensure you choose proper equipment and materials, file on time, avoid repeat studies, and more. Save your spot to be a part of this insightful discussion! 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
